Reuters logo
BRIEF-MabVax Therapeutics announces $1.25 mln registered direct offering
September 22, 2017 / 7:49 PM / in a month

BRIEF-MabVax Therapeutics announces $1.25 mln registered direct offering

Sept 22 (Reuters) - MabVax Therapeutics Holdings Inc:

* MabVax Therapeutics Holdings announces $1.25 million registered direct offering

* Each share of common stock is being sold at a price of $0.62 per share

* To use proceeds of offering to fund clinical development of HuMab 5B1 antibody designated MVT-5873 with gemcitabine, nab-paclitaxal​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below